Načítá se...
Radium-223 for the treatment of castration-resistant prostate cancer
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in p...
Uloženo v:
| Vydáno v: | Onco Targets Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4445785/ https://ncbi.nlm.nih.gov/pubmed/26056474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S44291 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|